Modality
Gene Therapy
MOA
PD-1i
Target
MDM2
Pathway
Fibrosis
Gastric Ca
Development Pipeline
Preclinical
~Jan 2022
→ ~Apr 2023
Phase 1
~Jul 2023
→ ~Oct 2024
Phase 2
Jan 2025
→ Mar 2028
Phase 2Current
NCT08181623
2,978 pts·Gastric Ca
2025-01→2028-03·Completed
2,978 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-262.0y awayPh3 Readout· Gastric Ca
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2/3
Complet…
Catalysts
Ph3 Readout
2028-03-26 · 2.0y away
Gastric Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08181623 | Phase 2/3 | Gastric Ca | Completed | 2978 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| ITO-535 | iTeos | NDA/BLA | MDM2 |